Try our Advanced Search for more refined results

Expert Analysis

PerkinElmer — A Sign Of What's To Come For Diagnostics

Law360, New York (February 28, 2013, 10:32 AM EST) -- Patent practitioners today are aware of the potential impact that a patentability inquiry under 35 U.S.C. § 101 may have on determining whether an invention is eligible for patent protection, including for those innovations within the biopharmaceutical arts. Providing the latest guidance on the patentability of diagnostic method patents, particularly as used in the growing field of personalized medicine, is the U.S. Supreme Court's March 2012 decision in Mayo Collaborative Svcs. v. Prometheus Labs. Inc.[1] and the Federal Circuit's August 2012 decision in Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office.[2]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!